Pharmacological treatments for prostate cancer

Expert Opinion on Investigational Drugs

Volumn 11, Issue 12, 2002, Pages 1737-1748

  Walczak, Janet R ^a   Carducci, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biphosphonates; Calcitriol; Chemotherapy; Endothelin receptor antagonists; Epothilones; Flavorpiridol; Immune strategies; Microtubule inhibitors; Prostate cancer; Taxanes taxoids

Indexed keywords

ANTIDIARRHEAL AGENT; ANTINEOPLASTIC AGENT; ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; BMS 310705; CALCITRIOL; CANCER VACCINE; CREMOPHOR; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; EPOTHILONE DERIVATIVE; ESTRAMUSTINE PHOSPHATE; FLAVOPIRIDOL; GLUCOSE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IXABEPILONE; MITOXANTRONE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; PREDNISONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; STEROID; TAXANE DERIVATIVE; TAXOID; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIDAZOLE DERIVATIVE; PYRROLIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ALOPECIA; ANEMIA; ANOREXIA; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG RESPONSE; DRUG TARGETING; DUODENUM ULCER; EDEMA; FATIGUE; HEADACHE; HUMAN; HYPERGLYCEMIA; MALE; MICROTUBULE; MOOD DISORDER; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; PROSTATE CANCER; REVIEW; RHINITIS; STOMACH ULCER; SYMPTOM; VASCULAR DISEASE; VERTIGO; DENDRITIC CELL; DRUG EFFECT; GENE THERAPY; GENETICS; IMMUNOLOGY; PROSTATE TUMOR;

ANTIBODIES, MONOCLONAL; DENDRITIC CELLS; DIPHOSPHONATES; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMIDAZOLES; MALE; MICROTUBULES; PROSTATIC NEOPLASMS; PYRROLIDINES; RADIOPHARMACEUTICALS;

EID: 0036906938     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.12.1737     Document Type: Review

References (76)

1. JEMAL A, THOMAS A, MURRAY T, THUN M: Cancer statistics, 2002. CA Cancer J. Clin. (2002) 52(1):23-46.
2. KANTOFF PW, HALABI S, CONAWAY M et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J. Clin. Oncol. (1999) 17(8):2506-2513.
3. TANNOCK IF, OSOBA D STOCKLER MR et al.: Chemotherapy with mitoxantrone and prednisone for symptomatic hormone refractory prostate cancer patients. J. Clin. Oncol. (1996) 14:1756-1764.
4. YINGMING L, TAKATSUGU O, LOMBARDI DP. FRENKEL EP, HSIEH JT: Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents. J. Urol. (2002) 167:339-346.
5. ROTH BJ, YEAP BY, WILDING G et al.: Taxol in advanced, hormone refractory carcinoma of the prostate: A Phase II trial of the Eastern Cooperative Oncology Group. Cancer (1993) 72:2457-2460.
6. TRIVEDI V, REDMAN B, FLAHERTY LE et al.: Weekly 1-hour infusion of paclitaxel: Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer(2000) 89:431.
7. PICUS J, SCHULTZ M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone refractory prostate cancer: Preliminary results. Semin. Oncol. (1999) 26(Suppl. 17):14.
8. BERRY W, ROHRBAUGH T, AMERICAN ONCOLOGY RESOURCES CLINICAL RESEARCH TASK FORCE: Phase II trial of single agent, weekly (wk) taxotere (t) in symptomatic, hormone-refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. (1999) (Abstract 18L335a).
9. BEER TM, PIERCE WC, LOWE BA, HENNER WD: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann. Oncol. (2002) 12(9):1273-1279.
10. HARTLEY-ASP B, KRUSE E: Nuclear protein matrix as a target for estramustine-induced cell death. Prostate (1986) 9:387-395.
11. HUDES GR, NATHAN F, KHATER C et al.: Phase II trial of 96 hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. (1997) 15:3156.
12. HUDES GR, MANOLA J, CONROY J, HABERMANN T, WILDING G: Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced-dose oral estramustine (EMP) in metastatic hormone-refractory prostate carcinoma (HRPC): A trial of the Eastern Cooperative Oncology Group. Proc. Am. Soc. Clin. Oncol. (2001) 20:175a.
13. PETRYLAK DP, MACARTHUR RB, O'CONNOR J et al.: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J. Clin. Oncol. (1999) 17(3):958-967.
14. PETRYLAK DP, SHELTON GB, ENGLAND-OWEN C et al.: Response and preliminary survival results of a Phase II study of docetaxel (D) + estramustine (E) in patients (Pts) with androgen-independent prostate cancer (AIPC). Proc. Am. Soc. Clin. Oncol. (2000) 19:334a. 1899.
15. SAVARESE D, TAPLIN ME, HALABI S et al.: A Phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer. J. Clin. Oncol. (2001) 26(Suppl. 17):39-44.
16. SINIBALDI VJ, CARDUCCI MA, MOORE-COOPER S, LAUFER M, ZAHURAK M, EISENBERGER MA: Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer (2002) 94:1457-1465.
17. COPUR MS, TARANTOLO SR, HAUKE R et al.: Weekly estramustine, taxotere, and dexamethasone in patients with hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:347a.
18. MORANT R, HSU SCHMITZ SE, BERNHARD J et al.: Vinorelbine in androgen-independent metastatic prostate carcinoma: A Phase II study. Eur. J. Cancer (2002) 38(12):1626-1632.
19. OUDARD S, CATY A, HUMBLET Y et al.: Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann. Oncol. (2001) 12(6):847-852.
20. SMITH MR, KAUFMAN D, OH W et al.: Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a Phase II study. Cancer (2000) 89(8):1824-1828.
21. SWEENEY CJ, MONACO FJ, JUNG SH et al.: A Phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann. Oncol. (2002) 13:435-440.
22. CORDER EH, GUESS HA, HULKA BS et al.: Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomarkers Prev. (1993) 2(5):467-472.
23. CHAN JM, GIOVANNUCCI E, ANDERSSON SO et al.: Dairy products, calcium, phosphorus, vitamin D, and risk of prostate cancer. Cancer Causes Control (1998) 9(6):559-566.
24. GIOVANNUCCI E: Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control (1998) 9(6):567-582.
25. SKROWRONSKI RJ, PEEHL DM, FELDMAN D: Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cells. Cancer Endocrinol. (1993) 132(5):1952-1960.
26. MILLER GJ, STAPLETON GE, FERRAR JA et al.: The human prostatic carcinoma cell in LNCaP expresses biologically active, specific receptors for I alpha, 25-dihydroxyvitamin D3. Cancer Res. (1992) 52(3):515-520.
27. ZHUANG SH, SCHWARTZ GG, CAMERON D, BURNSTEIN KL: Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell. Endocrinol. (1997) 126(1):83-90.
28. ZHAO XY, LY LH, PEEHL DM, FEKDNAB D: 1 alpha, 25 dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology (1997) 138(8):3290-3298.
29. YU WD, MCELWAIN MC, MODZELEWSKI RA et al.: Enhancement of 1,25 dihydroxyvitamin D30 mediated antitumor activity with dexamethasone. J. Natl. Cancer Inst. (1998) 90(2):134-141.
30. LOWE BA, HENNER WD, LEMMON DD et al.: Long-term administration of high dose weekly oral calcitriol in patients with a rising PSA after definitive treatment for prostate cancer (PC): A Phase II study. Proc. Am. Soc. Clin. Oncol. (2002) 21:158b.
31. BEER TM, EILERS KM, GARZOTTO M, LOWE BA, HENNER WD: Androgen-independent prostate cancer (AIPC) treatment with weekly high-dose calcitriol and docetaxel. Proc. Am. Soc. Clin. Oncol. (2002) 21:177a.
32. FIGG WD, DAHUT W, DURAY P et al.: A randomised Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. (2001) 7:1888-1893.
33. DAHUT WL, ARLEN PM, GULLEY J et al.: A randomised Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:183a.
34. LI Y, CHINNI SR, SENDEROWICZ AM et al.: Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. Int. J. Oncol. (2000) 17:755-759.
35. KAUR G, STELTER-STEVENSON M, SEBERS S et al.: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. (1992) 84:1736-1740.
36. THOMAS J, CLEARY J, TUTSCH K et al.: Phase I clinical and pharmacokinetic trial of flavopiridol. Proc. Am. Assoc. Cancer Res. (1997) 38:222a.
37. SENDEROWICZ AM, HEADLEE D, STINSON SF et al.: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor in patients with refractory neoplasms. J. Clin. Oncol. (1998) 16:2986-2999.
38. MOTWANI M, DELOHERY TM, SCHWARTZ GK: Sequential dependent enhancement of caspase activation andapoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res. (1999) 5:1876-1883.
39. BIBLE KC, KAUFMANN SH: Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration. Cancer Res. (1997) 57:3375-3380.
40. SCHWARTZ GK, O'REILLY E, ILSON D et al.: Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J. Clin. Oncol. (2002) 20(8):2157-2170.
41. MEKHAIL T, HOLDEN S, PIERSON S et al.: A Phase I pharmacokinetic and biologic study of the novel epothilone BMS-310750 in patients with advanced cancer. Proc. Amer. Soc. Clin. Oncol. (2002) 20:408a.
42. SMALETZ O, KELLY WK, HORSE-GRANT D et al.: Epothilone B analogue (BMS-247550) with estramustine phosphate (EMP) in patients (pts) with progressive castrate-metastatic prostate cancer (pc). Proc. Amer. Soc. Clin. Oncol. (2002) 20:732a.
43. YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411-415.
44. INOUE A, YANAGIWAWA M, KIMURE S et al.: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA (1989) 86:2863-2867.
45. KUSUHARA M, YAMAGUCHI K, NAGASAKE K et al.: Production of endothelin in human cancer cell lines. Cancer Res. (1990) 50(11):3257-3261.
46. NELSON JB, HEDICAN SP, GEORGE DJ et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. (1995) 1:944-949.
47. NELSON JB, CHAN-TACK K, HEDICAN SP et al.: Endothelin-1 production and decreased endothelin-B receptor expression in advanced prostate cancer. Cancer Res. (1996) 56:663-668.
48. GOHJI K, KITAZAWA S, YAMASHITA K et al.: The expression of endothelin receptor A associated with prostate cancer progression. J. Urol. (2001) 165(3):1033-1036.
49. CARDUCCI MA, NELSON JB, BOWLING MK et al.: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and Pharmacokinetics. J. Clin. Oncol. (2002) 20(8):2171-2180.
50. NELSON JB, CARDUCCI MA, ZONNENBERG et al.: Preliminary Phase II results using ABT-627, an endothelin-A selective receptor antagonist, in men with symptomatic hormone refractory prostate cancer. AUA 95th Annual Meeting, Anaheim, USA. J. Urol. (2000) 163:159.
51. CARDUCCI MA, NELSON JB, PADLEY RY, JANUS T, HIPPENSTEEL R: The endothelin-A receptor antagonist atrasentan (ABT-627) delays clinical progression in hormone refractory prostate cancer: a multinational, randomised, double-blind, placebo-controlled trial. Proc. Am. Soc. Clin. Oncol. (2001) 20:694a.
52. CARDUCCI MA, PADLEY RJ, BREUL J et al.: The effect of endothelin-A receptor blockade with atrasentan on tumor prgression in men with hormone refractory prostate cancer: A randomised, placebo controlled trial. J. Clin. Oncol (2002) (In press).
53. CARDUCCI MA, NELSON JB, HUMERICKHOUSE R, WEINBERG M, SCHMITT J, NABULSI A: Effects of atrasentan on progression and survival in men with hormone refractory prostate cancer: Follow-up to study M96-594. Proc. Am. Soc. Clin. Oncol. (2002) 21:178a.
54. BOSSIER S, FERRERAS M, PEYRUCHAUD O et al.: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastates. Cancer Res. (2000) 60(11):2949-2954.
55. LEE MV, FONG EM, SINGER FR, GUENETTE RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. (2001) 61(6):2602-2608.
56. COLEMAN RE, SEAMAN JJ: The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin. Oncol. (2001) 28(2, Suppl. 6):11-16.
57. SAAD F, GLEASON DM, MURRAY R et al.: A randomised, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. (2002) 94(19):1458-1468.
58. WITTERS L, CRISPINO J, JAVEED M et al.: Inhibition of growth of a human prostate cancer cell line with the combination of zoledronic acid and a COX-2 inhibitor. Proc. Am. Soc. Clin. Oncol. (2002) 21:5b.
59. TU SM, MILLIKAN RE, MENGISTU B et al.: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised Phase II trial. Lancet (2001) 357:336-341.
60. SIMONS JW, MIKHAK B, CHANG JF et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex-vivo gene transfer. Cancer Res. (1999) 59(20):5160-5168.
61. SIMONS JW, SMALL E, NELSON W et al.: Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX®) demonstrate anti-tumor activity. Proc. Amer. Soc. Clin. Oncol. (2001) 20:269a.
62. SIMONS J, NELSON W, NEMUNAITIS J et al.: Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc. Amer. Soc. Clin. Oncol. (2002) 21:183a.
63. RODRIGUEZ R, SCHUUR ER, LIM HY, HENDERSON GA, SIMONS JW, HENDERSON DR; Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. (1997) 57:2559-2563.
64. DeWEESE TL, VAN DER POEL H, LI S et al.: A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. (2001) 61(20):7464-7472.
65. CHEN Y, DeWEESE T, DILLEY J et al.: CN706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. (2001) 61:5453-5460.
66. YU DC, CHEN Y, SENG M, DILLEY J, HENDERSON DR: The addition of adenovirus Type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. (1999) 59(17):4200-4203.
67. YU DC, CHEN Y, DILLEY J et al.: Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. (2001) 61(2):517-525.
68. HWANG C, SANDA MG: Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Curr. Opin. Mol. Ther. (1999) 1(4):471-479.
69. SLOVIN SF: Vaccines as treatment strategies for relapsed prostate cancer: Approaches for induction of immunity. Hematol. Oncol. Clin. North Amer. (2001) 15(3):477-496.
70. ELZEY BD, SIEMENS DR, RATLIFF TL, LUBAROFF DM: Immunisation with Type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer (2001) 94(6):842-849.
71. BANDER NH, NANUS D, GOLDSMITH S et al.: Phase I trial of humanised monoclonal antibody (MAB) to prostate specific membrane antigen/extracellular domain (PSMAext). Proc. Am. Assoc. Cancer Res. (2001) 42:722a (Abstract).
72. 177Lutetuim (177L) in advanced prostate cancer (PCA). Proc. Am. Soc. Clin. Oncol. (2002) 21:5a.
73. NANUS DM, MILOWSKY MI, ROSMARIN AS et al.: Phase II trial of monoclonal antibody huj591 in combination with low dose subcutaneous interleukin-2 in patients with recurrent prostate cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:8b.
74. BURCH PA, BREEN JK, BUCKNER JC et al.: Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. (2000) 6(6):2175-2182.
75. SMALL EJ, FRATESI P, REESE DM et al.: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. (2000) 18(23):3879-3882.
76. FROLICH MW, SMALL EJ, BOK RA et al.: Immunotherapy with prostatic acid phosphatase-loaded dendritic cells (Provenge) in prostate cancer patients with serologic progression after definitive local therapy. Proc. Amer. Soc. Clin. Oncol. (2001) 20:750a.